(6-{[3-(pyridin-2-ylamino)propyl]thio}-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid | 402933-72-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (6-{[3-(pyridin-2-ylamino)propyl]thio}-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid
• 英文别名: 2-[6-[3-(Pyridin-2-ylamino)propylsulfanyl]-1,2,3,4-tetrahydronaphthalen-2-yl]acetic acid
• CAS: 402933-72-6
• 化学式: C₂₀H₂₄N₂O₂S
• 分子量: 356.489
• InChiKey: MEHCKTAYPGORPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  87.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Bicyclic alphavbeta3 antagonists
  申请人：——

  公开号：US20020072518A1

  公开（公告）日：2002-06-13

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; v &bgr; 3 and/or &agr; v &bgr; 5 integrin.

  本发明涉及一类由化学式I1表示的化合物或其药用可接受的盐，包括化合物I的药物组合物，以及选择性抑制或拮抗αvβ3和/或αvβ5整合素的方法。
• Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
  申请人：——

  公开号：US20040058915A1

  公开（公告）日：2004-03-25

  The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr;v&bgr; 3 and/or &agr;v&bgr; 5 integrin. The ring A-B, is selected from the group consisting of the formula II all optionally substituted and bonded to X and Z 1 at any position. 1

  本发明涉及一类由公式I或其药学上可接受的盐所表示的化合物、包含公式I化合物的药物组合物以及选择性抑制或拮抗αvβ3和/或αvβ5整合素的方法。环A-B选自由公式II表示的组中，所有位置均可选用取代基，并与X和Z1在任何位置结合。
• COMPOUNDS CONTAINING A BICYCLIC RING SYSTEM USEFUL AS ALPHA V BETA 3 ANTAGONISTS
  申请人：Pharmacia Corporation

  公开号：EP1320530A1

  公开（公告）日：2003-06-25
• [EN] COMPOUNDS CONTAINING A BICYCLIC RING SYSTEM USEFUL AS ALPHA V BETA 3 ANTAGONISTS<br/>[FR] COMPOSES CONTENANT UN SYSTEME DE NOYAU BICYCLIQUE ET UTILES EN TANT QU'ANTAGONISTES DE L'INTEGRINE ALPHA V BETA 3
  申请人：PHARMACIA CORP

  公开号：WO2002018377A1

  公开（公告）日：2002-03-07

  The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin. The ring A-B, is selected from the group consisting of the formula II all optionally substituted and bonded to X and Z1 at any position.